BTK and B-cell chronic lymphocytic leukemia: The most promising targeted therapies, including BCL-2 inhibitors and Bruton tyrosine kinase (BTK) inhibitors, are unable to offer a cure for CLL, while representing an economic burdensome with severe adverse events [5].